治疗帕金森病的丘脑下刺激短期焦虑结果的预测因素

IF 6.7 1区 医学 Q1 NEUROSCIENCES
Anna Sauerbier, Johanna Herberg, Vasilija Stopic, Philipp A. Loehrer, Keyoumars Ashkan, Alexandra Rizos, Stefanie T. Jost, Jan Niklas Petry-Schmelzer, Alexandra Gronostay, Christian Schneider, Veerle Visser-Vandewalle, Julian Evans, Christopher Nimsky, Gereon R. Fink, Angelo Antonini, Pablo Martinez-Martin, Monty Silverdale, Daniel Weintraub, Anette Schrag, K. Ray Chaudhuri, Lars Timmermann, Haidar S. Dafsari
{"title":"治疗帕金森病的丘脑下刺激短期焦虑结果的预测因素","authors":"Anna Sauerbier, Johanna Herberg, Vasilija Stopic, Philipp A. Loehrer, Keyoumars Ashkan, Alexandra Rizos, Stefanie T. Jost, Jan Niklas Petry-Schmelzer, Alexandra Gronostay, Christian Schneider, Veerle Visser-Vandewalle, Julian Evans, Christopher Nimsky, Gereon R. Fink, Angelo Antonini, Pablo Martinez-Martin, Monty Silverdale, Daniel Weintraub, Anette Schrag, K. Ray Chaudhuri, Lars Timmermann, Haidar S. Dafsari","doi":"10.1038/s41531-024-00701-6","DOIUrl":null,"url":null,"abstract":"<p>The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson’s disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively. We assessed the Hospital Anxiety and Depression Scale (HADS-anxiety and depression subscales), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-motor (SCOPA-M)-activities of daily living (ADL) and -motor complications, Non-Motor Symptom Scale (NMSS), PDQuestionnaire-8 (PDQ-8), and levodopa-equivalent daily dose. We tested changes at follow-up with Wilcoxon signed-rank test and corrected for multiple comparisons (Bonferroni method). We identified patients with a clinically relevant anxiety improvement of anxiety based on a designated threshold of ½ standard deviation of baseline HADS-anxiety. Moreover, we investigated predictors of HADS-anxiety changes with correlations and linear regressions. We included 50 patients with clinically relevant baseline anxiety (i.e., HADS-anxiety ≥ 8) aged 63.1 years ± 8.3 with 10.4 years ± 4.5 PD duration. HADS-anxiety improved significantly at 6-month follow-up as 80% of our cohort experienced clinically relevant anxiety improvement. In predictor analyses, worse baseline SCOPA-ADL and NMSS-urinary domain were associated with greater HADS-anxiety improvements. HADS-anxiety and PDQ-8 changes correlated moderately. Worse preoperative ADL and urinary symptoms predicted favourable postoperative anxiety outcome, which in turn was directly proportionate to greater QoL improvement. This study highlights the importance of detailed anxiety assessments alongside other non-motor and motor symptoms when advising and monitoring patients undergoing STN-DBS for PD.</p>","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":null,"pages":null},"PeriodicalIF":6.7000,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease\",\"authors\":\"Anna Sauerbier, Johanna Herberg, Vasilija Stopic, Philipp A. Loehrer, Keyoumars Ashkan, Alexandra Rizos, Stefanie T. Jost, Jan Niklas Petry-Schmelzer, Alexandra Gronostay, Christian Schneider, Veerle Visser-Vandewalle, Julian Evans, Christopher Nimsky, Gereon R. Fink, Angelo Antonini, Pablo Martinez-Martin, Monty Silverdale, Daniel Weintraub, Anette Schrag, K. Ray Chaudhuri, Lars Timmermann, Haidar S. Dafsari\",\"doi\":\"10.1038/s41531-024-00701-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson’s disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively. We assessed the Hospital Anxiety and Depression Scale (HADS-anxiety and depression subscales), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-motor (SCOPA-M)-activities of daily living (ADL) and -motor complications, Non-Motor Symptom Scale (NMSS), PDQuestionnaire-8 (PDQ-8), and levodopa-equivalent daily dose. We tested changes at follow-up with Wilcoxon signed-rank test and corrected for multiple comparisons (Bonferroni method). We identified patients with a clinically relevant anxiety improvement of anxiety based on a designated threshold of ½ standard deviation of baseline HADS-anxiety. Moreover, we investigated predictors of HADS-anxiety changes with correlations and linear regressions. We included 50 patients with clinically relevant baseline anxiety (i.e., HADS-anxiety ≥ 8) aged 63.1 years ± 8.3 with 10.4 years ± 4.5 PD duration. HADS-anxiety improved significantly at 6-month follow-up as 80% of our cohort experienced clinically relevant anxiety improvement. In predictor analyses, worse baseline SCOPA-ADL and NMSS-urinary domain were associated with greater HADS-anxiety improvements. HADS-anxiety and PDQ-8 changes correlated moderately. Worse preoperative ADL and urinary symptoms predicted favourable postoperative anxiety outcome, which in turn was directly proportionate to greater QoL improvement. This study highlights the importance of detailed anxiety assessments alongside other non-motor and motor symptoms when advising and monitoring patients undergoing STN-DBS for PD.</p>\",\"PeriodicalId\":19706,\"journal\":{\"name\":\"NPJ Parkinson's Disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2024-06-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Parkinson's Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41531-024-00701-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Parkinson's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41531-024-00701-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

眼下核深部脑刺激(STN-DBS)对帕金森病(PD)患者焦虑的影响尚未得到充分研究。在这项研究中,我们确定了 STN-DBS 对焦虑影响的临床预测因素。在这项前瞻性、开放标签、多中心研究中,我们对接受 STN-DBS 治疗的帕金森病焦虑症患者进行了术前评估和术后 6 个月随访。我们评估了医院焦虑抑郁量表(HADS-焦虑和抑郁分量表)、统一帕金森病评分量表-运动检查、帕金森病结果量表-运动(SCOPA-M)-日常生活活动(ADL)和运动并发症、非运动症状量表(NMSS)、帕金森病问卷-8(PDQ-8)和左旋多巴当量日剂量。我们采用 Wilcoxon 符号秩检验检验随访时的变化,并进行多重比较校正(Bonferroni 方法)。我们根据基线 HADS-焦虑的 1/2标准差这一指定阈值,确定了焦虑程度有临床相关性改善的患者。此外,我们还通过相关性和线性回归研究了 HADS-焦虑变化的预测因素。我们纳入了 50 名具有临床相关基线焦虑(即 HADS-anxiety ≥ 8)的患者,他们的年龄为 63.1 岁 ± 8.3 岁,PD 病程为 10.4 年 ± 4.5 年。在6个月的随访中,HADS-焦虑明显改善,80%的患者焦虑得到了临床相关的改善。在预测因素分析中,基线 SCOPA-ADL和 NMSS-泌尿领域较差与 HADS-焦虑改善程度较大相关。HADS-anxiety 和 PDQ-8 的变化呈中度相关。术前 ADL 和泌尿系统症状较差预示着术后焦虑状况良好,而术后焦虑状况良好又与 QoL 改善程度成正比。本研究强调了在建议和监测接受 STN-DBS 治疗的帕金森病患者时,详细的焦虑评估以及其他非运动症状和运动症状的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease

Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease

The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson’s disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively. We assessed the Hospital Anxiety and Depression Scale (HADS-anxiety and depression subscales), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-motor (SCOPA-M)-activities of daily living (ADL) and -motor complications, Non-Motor Symptom Scale (NMSS), PDQuestionnaire-8 (PDQ-8), and levodopa-equivalent daily dose. We tested changes at follow-up with Wilcoxon signed-rank test and corrected for multiple comparisons (Bonferroni method). We identified patients with a clinically relevant anxiety improvement of anxiety based on a designated threshold of ½ standard deviation of baseline HADS-anxiety. Moreover, we investigated predictors of HADS-anxiety changes with correlations and linear regressions. We included 50 patients with clinically relevant baseline anxiety (i.e., HADS-anxiety ≥ 8) aged 63.1 years ± 8.3 with 10.4 years ± 4.5 PD duration. HADS-anxiety improved significantly at 6-month follow-up as 80% of our cohort experienced clinically relevant anxiety improvement. In predictor analyses, worse baseline SCOPA-ADL and NMSS-urinary domain were associated with greater HADS-anxiety improvements. HADS-anxiety and PDQ-8 changes correlated moderately. Worse preoperative ADL and urinary symptoms predicted favourable postoperative anxiety outcome, which in turn was directly proportionate to greater QoL improvement. This study highlights the importance of detailed anxiety assessments alongside other non-motor and motor symptoms when advising and monitoring patients undergoing STN-DBS for PD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
NPJ Parkinson's Disease
NPJ Parkinson's Disease Medicine-Neurology (clinical)
CiteScore
9.80
自引率
5.70%
发文量
156
审稿时长
11 weeks
期刊介绍: npj Parkinson's Disease is a comprehensive open access journal that covers a wide range of research areas related to Parkinson's disease. It publishes original studies in basic science, translational research, and clinical investigations. The journal is dedicated to advancing our understanding of Parkinson's disease by exploring various aspects such as anatomy, etiology, genetics, cellular and molecular physiology, neurophysiology, epidemiology, and therapeutic development. By providing free and immediate access to the scientific and Parkinson's disease community, npj Parkinson's Disease promotes collaboration and knowledge sharing among researchers and healthcare professionals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信